A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Radiation therapy improves cancer cure rates by killing cancer cells but it also contributes to long-term side effects in cancer survivors by unintentionally damaging normal organs such as the intestine. This research will what side effects patients with cancer experience, if high dose vitamin C helps reduce these side effects, and if high dose vitamin C increases the survival of patients with pancreatic cancer. We will meet with patients during the study to better understand their experience during their cancer treatment. In the long term, our research could provide a new way help cancer survivors avoid many permanent side effects of cancer treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

NCT01852890

Pancreatic Neoplasms

COMPLETED PHASE1

A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer

NCT01049880

Pancreatic Neoplasms

COMPLETED PHASE1

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03908333

Metastatic Pancreatic Cancer Pancreatic Cancer Pancreas Cancer +3 more

WITHDRAWN PHASE1/PHASE2

Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca

NCT01555489

Stage IV Pancreatic Cancer

TERMINATED PHASE2

Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

NCT01515046

Pancreatic Neoplasms Pancreatic Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized phase 2 study is designed to determine initial efficacy and assess adverse events, and quantify pathologic evidence of intestinal radiation injury. The ascorbate is infused before, during, and after the external beam radiation therapy treatment. Each ascorbate infusion is 75 grams (roughly the same amount of vitamin C from 1,000 oranges).

For patients eligible for this trial, standard treatment for their cancer includes radiation therapy combined with weekly gemcitabine (a chemotherapy).

Participants will:

* be randomized (like flipping a coin) to receive the investigational treatment (pharmacological ascorbate plus gemcitabine plus radiation) or standard treatment only (gemcitabine plus radiation)
* receive gemcitabine (a chemotherapy) once a week for up to 6 weeks of therapy (all participants)
* receive radiation treatments are given once a day, Monday through Friday (all participants).
* have routine doctor's visits and be asked about any side effects they are experiencing (all participants).
* be interviewed to discuss their side effects, how it impacts their life, and describe their recent activities.
* receive pharmacological ascorbate intravenously ascorbate during their daily radiation therapy treatments (if randomized to receive the investigational treatment).

Once the patient completes radiation, the ascorbate infusions are also completed. However, the patient will need to return for regular follow-up care at University of Iowa. We are interested in the long-term side effects of radiation - which may not develop for years - so it is important the participant return to radiation oncology for follow-up. We will also conduct interviews at that time to review the side effects and how they impact the participant's quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized trial (standard vs. experimental) in a one-to-one ratio.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Radiologic measurements will be completed by a reviewer blinded to treatment assignment

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational Therapy (ASC)

75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique

Group Type EXPERIMENTAL

Ascorbate

Intervention Type DRUG

75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.

Gemcitabine

Intervention Type DRUG

600 mg/m2 once weekly for up to weeks

radiation therapy

Intervention Type RADIATION

Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.

Standard Therapy (ChemoRT)

600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique

Group Type ACTIVE_COMPARATOR

Gemcitabine

Intervention Type DRUG

600 mg/m2 once weekly for up to weeks

radiation therapy

Intervention Type RADIATION

Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ascorbate

75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.

Intervention Type DRUG

Gemcitabine

600 mg/m2 once weekly for up to weeks

Intervention Type DRUG

radiation therapy

Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ascor L 500 Pharmacological ascorbate Vitamin C Gemzar Volumetric Arc Therapy (VMAT) External beam radiation therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible to participate in this study, an individual must meet ALL of the following criteria:

* Ability and willingness to provide informed consent (power of attorney and legally authorized representatives are not accepted for informed consent)
* Stated willingness to comply with all study procedures and availability for duration of the study
* At least 18 years of age
* Histologic or cytologic diagnosis of pancreatic adenocarcinoma
* Referral for gemcitabine-based chemoradiation
* Good performance status (ECOG of 0, 1, or 2; KPS of \> 50)
* No other active malignancy that requires immediate treatment. Slow growing concurrent cancers (such as prostate cancer) are acceptable with appropriate documentation from their treating oncologists for that primary.
* Not experiencing an uncontrolled illness such as infection requiring inpatient admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any other condition that would limit compliance with the study requirements or unacceptably increase risk to the participant (as determined by study team members).
* Agree to abstain from alcohol and specified over the counter supplements during study treatment

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participating in this study:

* Glucose-6-phosphate dehydrogenase (G6PD) deficiency
* HIV positive individuals requiring anti-retroviral drug therapy (high-dose ascorbate is known to interact with many of these drugs)
* Platelet count of \<100,000 k/mm3
* Prior radiation that would result in field overlap (this will be determined by the study's radiation oncologist)
* Presence of metastatic disease beyond regional lymphatics
* Actively receiving insulin
* Other therapy (including radiation therapy) within 2 calendar weeks of study therapy
* On any of the following drugs and cannot or will not accept a drug substitution: warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide
* Other investigational agents (PET or SPECT imaging agents are acceptable)
* Other investigational therapy with the intention to treat the disease under study
* Pregnancy
* Individuals declining to use acceptable birth control during the duration of the study
* Lactating women who decline to discontinue breastfeeding their child (women may withhold breast feeding and resume under the direction of their medical oncologist after completion of study)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No